On September 16, the list of Hunan Top 100 Manufacturing Enterprises in 2024 was released, with Jiudian Pharmaceutical ranking 76th—an increase of 10 places compared to 2023 and a record high in the company’s history. This breakthrough achievement not only demonstrates the remarkable results of the enterprise’s innovation-driven development and industrial upgrading but also reflects the strong growth momentum of Hunan’s biomedical industry cluster.

As a national high-tech enterprise, Jiudian Pharma has focused on the high-end pharmaceutical preparation field and built a full industrial chain layout from active pharmaceutical ingredients (APIs) to preparations. Over the past three years, the company has maintained steady growth in its operating performance. Its core products, such as Loxoprofen Sodium Gel Patch and Ketoprofen Gel Patch, have achieved annual sales of nearly 1.6 billion yuan, establishing a leading position in the field of external anti-inflammatory and analgesic products.

In terms of innovative drug research and development, Jiudian Pharma focuses on the dual-track development of traditional Chinese medicine (TCM) and chemical drugs: The TCM innovative drug Jiaoqi Zhitong Gel Patch has completed clinical research and filed for production, while a number of innovative chemical drugs and improved new drugs have entered the clinical stage. Simultaneously, the company has promoted the upgrading of intelligent manufacturing, improved production efficiency through digital transformation, and was awarded the title of "Hunan Advanced-Level Intelligent Factory".

Jiudian Pharma will continue to uphold its core philosophy of "Integrating Chinese and Western Medicines, Committed to Health", keep deepening its presence in the transdermal drug delivery field, accelerate the R&D of innovative drugs, and strive to become a leading enterprise in China’s transdermal drug delivery sector, contributing to the high-quality development of Hunan’s manufacturing industry.